CBLL · Ceribell, Inc. · Webcasts, Transcripts & Audio
$26.14
-0.21 (-0.80%)
At close · Nov 13
Return incl. dividend (before tax)
Play latest call
Q3 2026 earnings call transcript
Market Cap
$1.02B
Shares
38.84M
Volume · Nov 13
267.65K
Avg daily vol (3M)
441.74K
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Ceribell, Inc. Webcasts
Earnings calls, investor updates, investor days and conferences for Ceribell, Inc. (CBLL), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.
Pull transcripts and briefs through the earnings call transcript API or MCP →
Add these events to your calendar (.ics)
Earnings call
FY26 · Q3
2026-11-03
Ceribell, Inc. (CBLL) Q3 2026 Earnings Call Transcript
Revenue
$29.34M
▲ 29.9% YoY Diluted EPS
$-0.55
Gross margin
89.8%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Conference
Investor event
2026-08-12
Ceribell, Inc. (CBLL) August 12, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q2
2026-08-10
Ceribell, Inc. (CBLL) Q2 2026 Earnings Call Transcript
Confident tone
New AI Algorithms
Gross Margin
Hardware Platform Expansion
Revenue
$28.10M
▲ 32.5% YoY Diluted EPS
$-0.51
Gross margin
92.3%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Conference
Investor event
2026-06-03
Ceribell, Inc. (CBLL) June 3, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-05-13
Ceribell, Inc. (CBLL) May 13, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q1
2026-05-11
Ceribell, Inc. (CBLL) Q1 2026 Earnings Call Transcript
Confident tone
Headband utilization and same-store growth
Neonate and pediatric product launches
Gross margin and profitability outlook
Revenue
$26.49M
▲ 29.3% YoY Diluted EPS
$-0.52
Gross margin
87.3%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q4
2026-02-24
Ceribell, Inc. (CBLL) Q4 2025 Earnings Call Transcript
Confident tone
Neonate and pediatric FDA clearance
Standard of care / point-of-care EEG vision
VA / FedRAMP opportunity
Revenue
$24.78M*
▲ 33.7% YoY Gross margin
87.3%
Rev · 7q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY25 · Q3
2025-11-04
Ceribell, Inc. (CBLL) Q3 2025 Earnings Call Transcript
Confident tone
Revenue growth and guidance raise
Active account expansion
Standard of care / category leadership vision
Revenue
$22.59M
▲ 31.4% YoY Diluted EPS
$-0.37
Gross margin
88.3%
Rev · 7q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2025-08-05
Ceribell, Inc. (CBLL) Q2 2025 Earnings Call Transcript
Confident tone
Delirium product development
Commercial expansion and territory build-out
Neonate / NICU pilot and expansion
Revenue
$21.20M
▲ 38.4% YoY Diluted EPS
$-0.38
Gross margin
88.1%
Rev · 6q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2025-05-08
Ceribell, Inc. (CBLL) Q1 2025 Earnings Call Transcript
Confident tone
Gross Margin and Pricing
Pediatric Clarity Clearance
Commercial Expansion
Revenue
$20.49M
▲ 42.3% YoY Diluted EPS
$-0.36
Gross margin
87.9%
Rev · 5q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2025-02-25
Ceribell, Inc. (CBLL) Q4 2024 Earnings Call Transcript
Confident tone
Clinical impact and patient stories
Revenue growth and financial performance
Account acquisition and sales force expansion
Revenue
$18.53M*
Gross margin
87.6%
Rev · 4q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-11-12
Ceribell, Inc. (CBLL) Q3 2024 Earnings Call
Revenue
$17.20M
▲ 48.1% YoY Diluted EPS
$-1.85
Gross margin
87.3%
Rev · 4q
Audio
Transcript
Slides
8-K10-Q
Showing 1–12 of 12 webcasts
Key facts
CIK
1861107
CUSIP
15678C102
13F (30d)
87 filings
84 filers
Visit website
Investor relations